A recent study has demonstrated that a K-RasG12C inhibitor potentiates the anticancer effect of the MEK, mTOR, and insulin-like growth factor 1 receptor (IFG1R) inhibitors in NSCLC cells. Here, IGF1R is linked to non-small cell lung carcinoma.